1 June 2019 in Ortadoğu Tıp Dergisi
En tr Objectives: Pulmonary giant cell carcinoma (PGCC) is a histological type of nonsmall cell lung cancer and classified as one of the five subtypes of sarcomatoid carcinoma of the lung. Pure PGCC is very rare. Material and Method: We represent our experience in the management of 7 patients (6 males and 1 female, with a range of 44-63 yr) with PGCC. The most representing symptoms were cough and hemoptysis. Upper lobectomy (n=7) and additionally mediastinal lymphadenectomy were performed in all patients. Results: Definitive histological examination confirmed the diagnosis of PGCC in all cases. Even though there was no perioperative mortality, postoperative complications developed in a case were hemorrhage in the early perioperative period and bronchus fistula after two months from the operation. The mean survival of the patients was estimated as 28.8 months (38 days - 116 months). Conclusion: The main treatment for PGCC is the complete surgical resection. Complete surgical resection was found to be usefull as a treatment of choice of PGCC in the early stage and contributed to survival. Amaç: Pulmoner dev hücreli karsinom (PDHK) küçük hücreli dışı akciğer kanserinin bir histolojik tipidir ve akciğer sarkomatoid karsinomunun beş subtipinden biri olarak sınıflandırılır. Pür PDHK çok nadirdir. Gereç ve Yöntem: Kliniğimizde PDHK nedeni ile tedavi gören 7 hastayla ilgili tecrübelerimizi sunduk (6 erkek ve 1 kadın, yaş aralığı 46-63 yıl). En sık görülen semptomlar öksürük ve hemoptizi idi. Üst lobektomi (n=7) ve ek olarak mediastinal lenfadenektomi bütün hastalara uygulandı. Bulgular: Kesin histolojik inceleme ile tüm hastalarda PDHK tanısı doğrulandı. Herhangi bir perioperatif mortalite görülmemesine rağmen bir olguda ameliyat sonrası komplikasyon gelişti; erken perioperatif dönemde hemoraji ve operasyondan iki ay sonra bronşiyal fistül gelişti. Hastaların ortalama sağkalımı 28,8 ay (38 gün-116 ay) olarak bulundu. Sonuç: PDHK için asıl tedavi komplet cerrahi rezeksiyondur. Komplet cerrahi rezeksiyonun erken evre PDHK için yararlı bir tedavi tercihi olduğu ve sağkalıma katkı sağladığı bulunmuştur.
31 May 2023 in Journal of Health Sciences and Medicine
Aim: Psychiatric disorders are common in patients with advanced respiratory diseases. The prevalence of primary spontaneous pneumothorax ranges from 1.2-37 per 100,000 population per year, and the risk of recurrence causes anxiety and depression for the patients. Material and Method: The Hospital Anxiety and Depression (HAD) scale was applied to 50 patients with a primary spontaneous pneumothorax that underwent treatment in our clinic and a control group of 50 individuals. The study and control group had similar participants (50 patients, 9 women and 41 men). The control group comprised otherways healthy participans aged between 18-40 who had admitted to the smoking cessation clinic. Results: While the study group's mean age was 25.2, it was 29 in the control group (covariance analysis used for the correction). On anxiety scale, the study group's mean score was calculated as 8.6, while it was 5.7 in the control group. The difference was found to be significantly higher in the patient group. The depression scale score of the study group was 5.8, and the control group's score was 5.7. There was no statistically significant difference between the groups. Conclusion: Since pneumothorax is a sudden, recurring, and severe illness that can cause respiratory distress, it may lead to anxiety or depression in patients. Without treatment, life-threatening consequences such as dyspnea and cardiac collapse may occur. Furthermore, the painful procedure of tube thoracostomy increases the patients' anxiety. Our objective is to identify potential anxiety-depression in pneumothorax patients, leading to improved mental health outcomes, increased satisfaction, lower readmission rates, and reduced care costs.